Macleods Pharmaceuticals Limited — Pyrazinamide Exporter Profile
Indian Pharmaceutical Exporter · #3 for Pyrazinamide · $25.2M export value · DGFT Verified
Macleods Pharmaceuticals Limited is the #3 Indian exporter of Pyrazinamide with $25.2M in export value and 143 verified shipments. Macleods Pharmaceuticals Limited holds a 1.9% market share in Pyrazinamide exports across 51 countries. The company exports 64 pharmaceutical products worth $589.8M across 20 therapeutic categories.
Macleods Pharmaceuticals Limited — Pyrazinamide Export Profile: Buyers & Destinations
Where Does Macleods Pharmaceuticals Limited Export Pyrazinamide?
| Country | Value | Shipments | Share |
|---|---|---|---|
| SOUTH AFRICA | $1.2M | 39 | 12.6% |
| NETHERLANDS | $1.2M | 54 | 11.9% |
| PAKISTAN | $623.0K | 15 | 6.4% |
| UNITED STATES | $418.6K | 24 | 4.3% |
| NIGERIA | $382.7K | 8 | 3.9% |
| RUSSIA | $350.0K | 7 | 3.6% |
| CAMBODIA | $300.0K | 6 | 3.1% |
| AFGHANISTAN | $298.0K | 9 | 3.1% |
| COTE D IVOIRE | $274.1K | 14 | 2.8% |
| KENYA | $257.7K | 8 | 2.6% |
Macleods Pharmaceuticals Limited exports Pyrazinamide to 104 countries. The largest destination is SOUTH AFRICA accounting for 12.6% of Macleods Pharmaceuticals Limited's Pyrazinamide shipments, followed by NETHERLANDS (11.9%) and PAKISTAN (6.4%). These destinations reflect Macleods Pharmaceuticals Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Pyrazinamide from Macleods Pharmaceuticals Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| I+SOLUTIONS | NETHERLANDS | $638.4K | 33 |
| MACLEODS PHARMACEUTICALS SA | SOUTH AFRICA | $565.0K | 16 |
| MACLEODS PHARMACEUTICALS SA (PTY) L | SOUTH AFRICA | $331.9K | 16 |
| MACLEODS PHARMA USA INC | UNITED STATES | $288.0K | 12 |
| NOUVELLE PSP CI | COTE D IVOIRE | $274.1K | 14 |
| IDA FOUNDATION | NETHERLANDS | $257.4K | 10 |
| ADVANCED PHARMACEUTICALS LIMITED | RUSSIA | $250.0K | 5 |
| IDA FOUNDATION, | NETHERLANDS | $237.7K | 9 |
| NATIONAL TB CONTROL PROGRAM,PAKISTA | PAKISTAN | $223.0K | 7 |
| NATIONAL TB CONTROL PROGRAMME, PAKI | PAKISTAN | $200.0K | 4 |
Macleods Pharmaceuticals Limited supplies Pyrazinamide to 176 buyers globally. The largest buyer is I+SOLUTIONS (NETHERLANDS), followed by MACLEODS PHARMACEUTICALS SA (SOUTH AFRICA) and MACLEODS PHARMACEUTICALS SA (PTY) L (SOUTH AFRICA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Pyrazinamide Export Value and How Much Does Macleods Pharmaceuticals Limited Contribute?
India exported $50.2M worth of Pyrazinamide through 1,459 shipments from 90 suppliers to 131 countries, serving 434 buyers globally. Macleods Pharmaceuticals Limited contributes $25.2M to this total, accounting for 1.9% of India's Pyrazinamide exports. Macleods Pharmaceuticals Limited ships Pyrazinamide to 104 countries through 176 buyers.
What Is the Average Shipment Value for Macleods Pharmaceuticals Limited's Pyrazinamide Exports?
Macleods Pharmaceuticals Limited's average Pyrazinamide shipment value is $176.2K per consignment, based on 143 shipments totaling $25.2M. The largest destination is SOUTH AFRICA (12.6% of Macleods Pharmaceuticals Limited's Pyrazinamide exports).
How Does Macleods Pharmaceuticals Limited Compare to Other Indian Pyrazinamide Exporters?
Macleods Pharmaceuticals Limited ranks #3 among 90 Indian Pyrazinamide exporters with a 1.9% market share. The top 3 exporters are MACLEODS PHARMACEUTICALS LTD ($18.1M), LUPIN LIMITED ($16.1M), MACLEODS PHARMACEUTICALS LIMITED ($7.2M). Macleods Pharmaceuticals Limited processed 143 shipments to 51 destination countries.
What Pyrazinamide Formulations Does Macleods Pharmaceuticals Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| RIFAMPICIN 75MG/ISONIAZID 50MG/ PYRAZINAMIDE 150MG DISPERSIBLE TABLETS,PACK 63,975 (PACK SIZE 3 X 28 TABS)NOS | $150.0K | 3 |
| RIFAMPICIN 75MG/ISONIAZID 50MG/PYRAZINAMIDE 150MG DISPERSIBLE TABLETS BNO.NRU2449A, NRU2450A MD.11/24 ED.10/26 PS:3X28S | $150.0K | 3 |
| PATIENT KIT(FORECOX TRAC) (RIFAMPICIN 150MG+ISONIAZID 75MG+PYRAZINAMIDE 400MG+ETHAMBUTOL 275MG TABLETS USP)NOS | $150.0K | 3 |
| RIFAMPICIN 150MG/ ISONIAZID 75MG /PYRAZINAMIDE 400MG/ ETHAMBUTOL HCL 275MG TABLETS ( 3672 X 24 X28S) DRUGS AND PHARMACENOS | $150.0K | 3 |
| DRUGS AND PHARMACEUTICALS HARMLESS MEDICINES RIFAMPICIN ISONIAZID AND PYRAZINAMIDE TABLETS (150MG+150MG+375 MG)NOS | $150.0K | 3 |
| MEDICINES. RIFAMPICIN 150MG + ISONIAZID 75MG + PYRAZINAMIDE 400MG + ETHAMBUTOL 275MG TABLETS | $150.0K | 3 |
| RIFAMPICIN 150MG/ISONIAZID 75MG/PYRAZINAMIDE 400/ETHAMBUTOL 275MG TABLET PS: 24X28S BNO:NRG23110C MD.12/23 ED.11/26**** | $146.5K | 3 |
| RIFAMPICIN 75MG / ISONIAZID 50MG / PYRAZINAMIDE 150MG DISPERSIBLE TABLETS | $144.0K | 3 |
| DRUGS AND PHARMACEUTICALS HARMLESS MEDICINES RIFAMPICIN ISONIAZID PYRAZINAMIDE AND ETHAMBUTOL HYDROCHLORIDE TABLETS USP | $138.3K | 4 |
| RIFAMPICIN 75MG/ISONIAZID 50MG/PYRAZINAMIDE 150MG DISPERSIBLE TAB.,B/N:NRU2403A/NRU2405A/NRU2404A,M.D.JAN-24,E.D.DEC-25 | $132.7K | 3 |
Macleods Pharmaceuticals Limited exports 333 distinct Pyrazinamide formulations including tablets, capsules, syrups, and combination drugs. The top formulation is RIFAMPICIN 75MG/ISONIAZID 50MG/ PYRAZINAMIDE 150MG DISPERSIB with 3 shipments worth $150.0K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
Regulatory Requirements: Exporting Pyrazinamide to Key Markets
What Macleods Pharmaceuticals Limited must comply with to export Pyrazinamide to its top destination countries
South Africa — SAHPRA
Approval Process
Registration under SAHPRA guidelines (CTD format). Bioequivalence required for generics.
Timeline: 24–48 months (significant backlog)
GMP & Export Requirements
WHO GMP or PIC/S GMP compliance
Certificate of Pharmaceutical Product from CDSCO; Import permit per Section 22A of Medicines Act
Note: Known registration backlog. WHO Prequalification significantly assists the process.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Macleods Pharmaceuticals Limited Compare to Nearest Pyrazinamide Exporters?
Exporters ranked immediately above and below #3 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 2 | MACLEODS PHARMACEUTICALS LTD | $18.1M | 361 | 84 | $50.0K |
| 1 | LUPIN LIMITED | $16.1M | 321 | 49 | $50.0K |
| 3 | MACLEODS PHARMACEUTICALS LIMITED ★ | $7.2M | 143 | 51 | $50.0K |
| 4 | MANEESH PHARMACEUTICALS LIMITED | $3.5M | 69 | 24 | $50.0K |
| 5 | SVIZERA LABS PRIVATE LIMITED | $1.9M | 39 | 12 | $50.0K |
Macleods Pharmaceuticals Limited ranks #3 among 90 Indian Pyrazinamide exporters. Average shipment value of $50.0K compared to the market average of $557.3K. The closest competitors by value are MACLEODS PHARMACEUTICALS LTD and LUPIN LIMITED.
Which Indian Ports Ship Pyrazinamide Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 357 | 24.5% |
| SAHAR AIR CARGO ACC (INBOM4) | 170 | 11.7% |
| DELHI AIR | 154 | 10.6% |
| DELHI AIR CARGO ACC (INDEL4) | 126 | 8.6% |
| Bombay Air | 94 | 6.4% |
| NHAVA SHEVA SEA (INNSA1) | 87 | 6.0% |
| JNPT | 87 | 6.0% |
| JNPT/ NHAVA SHEVA SEA | 81 | 5.6% |
What Other Tuberculosis Medications Products Does Macleods Pharmaceuticals Limited Export?
Macleods Pharmaceuticals Limited also exports these tuberculosis medications products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Macleods Pharmaceuticals Limited's Pyrazinamide Exports
The current geopolitical climate presents both challenges and opportunities for Indian pharmaceutical exporters like Macleods Pharmaceuticals. The Israel-Iran tensions have escalated security risks in the Red Sea and Strait of Hormuz, leading to increased shipping costs and extended transit times. Major carriers have rerouted vessels around the Cape of Good Hope, adding 10–20 days to shipments and raising freight rates by 40–50% on key India–Europe routes. (livemint.com)
Conversely, the U.S.-China trade tensions have opened avenues for Indian pharmaceutical companies to capture a larger share of the U.S. market. However, potential U.S. tariffs on Indian pharmaceutical imports pose a significant risk. A 25% tariff could render many low-margin generic drugs unprofitable, compelling companies to scale back operations or exit certain product segments, thereby exacerbating drug shortages in the U.S. (cfo.economictimes.indiatimes.com)
The recent India–European Union Free Trade Agreement, signed in January 2026, offers a favorable development by eliminating tariffs on most pharmaceutical products. This agreement is expected to enhance the competitiveness of Indian exporters in the EU market, providing a counterbalance to challenges in other regions. (en.wikipedia.org)
Macleods Pharmaceuticals Limited — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards remains a cornerstone for Indian pharmaceutical exporters. Macleods Pharmaceuticals' recent recalls in the U.S. market, including the Famciclovir tablet recall due to contamination, highlight the critical need for stringent adherence to Good Manufacturing Practices (GMP). Such incidents can tarnish a company's reputation and impede market access. (pharma.economictimes.indiatimes.com)
The evolving regulatory landscape, including the EU's Falsified Medicines Directive, necessitates robust serialization and traceability measures. Indian exporters must invest in advanced compliance systems to meet these requirements, ensuring product integrity and sustaining export growth.
About Macleods Pharmaceuticals Limited
Macleods Pharmaceuticals Limited exports 64 products worth $589.8M. Beyond Pyrazinamide, top products include Isoniazid, Rifampicin, Tenofovir, Valsartan, Artemether. View the complete Macleods Pharmaceuticals Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Pyrazinamide — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Pyrazinamide shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Macleods Pharmaceuticals Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 504 individual customs records matching Macleods Pharmaceuticals Limited exporting Pyrazinamide, covering 333 formulations to 104 countries via 176 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 131+ countries, 434+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Pyrazinamide Export Data from Macleods Pharmaceuticals Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Macleods Pharmaceuticals Limited's Pyrazinamide exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Macleods Pharmaceuticals Limited
Full Company Profile →
64 products · $589.8M total trade · 20 categories
Pyrazinamide Stats
Company Overview
Top Products by Macleods Pharmaceuticals Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Macleods Pharmaceuticals Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Pyrazinamide. For current shipment-level data, contact TransData Nexus.